Literature DB >> 2670533

Human lung deposition of particles suspended in air or in helium/oxygen mixture.

M Svartengren1, M Anderson, K Philipson, P Camner.   

Abstract

Deposition in mouth and throat and the fraction of alveolarly deposited particles in the lung of 3.6- to 3.8-microns Teflon particles labeled with 99mTc were estimated in nine healthy subjects. The particles were inhaled in air or helium/oxygen mixture with a flow of 0.5 l/s by subjects with or without induced bronchoconstriction. The bronchoconstriction (two- to threefold increase in airway resistance) was induced by an aerosol of methacholine bromide. As the Reynolds number is three times lower for the helium/oxygen mixture than for air, and the sedimentation rate of the particles is about the same in both, a different regional deposition between particles suspended in air and helium/oxygen mixture should be due to turbulence. Deposition in mouth and throat did not differ significantly between air and the helium/oxygen mixture. The alveolarly deposited fraction tended to be larger for unconstricted airways and was significantly larger for constricted airways for inhalations in the helium/oxygen mixture compared to air. In real life, air pollutants and therapeutic aerosols may be inhaled with larger flow rates and broncho-constriction may be more pronounced in patients, so that deposition of particles due to turbulence can be important.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670533     DOI: 10.3109/01902148909069619

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  7 in total

Review 1.  Aerosol deposition in health and disease.

Authors:  Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-06       Impact factor: 2.849

2.  Aerosol deposition in the human respiratory tract breathing air and 80:20 heliox.

Authors:  Chantal Darquenne; G Kim Prisk
Journal:  J Aerosol Med       Date:  2004

3.  Aerosol deposition in the human lung periphery is increased by reduced-density gas breathing.

Authors:  Jonathan B Peterson; G Kim Prisk; Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-06       Impact factor: 2.849

4.  Total and regional deposition of inhaled aerosols in supine healthy subjects and subjects with mild-to-moderate COPD.

Authors:  Chantal Darquenne; Wayne J Lamm; Janelle M Fine; Richard A Corley; Robb W Glenny
Journal:  J Aerosol Sci       Date:  2016-04-30       Impact factor: 3.433

Review 5.  Aerosol deposition in the human lung in reduced gravity.

Authors:  Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-06       Impact factor: 2.849

6.  Regional Ventilation and Aerosol Deposition with Helium-Oxygen in Bronchoconstricted Asthmatic Lungs.

Authors:  Elliot Eliyahu Greenblatt; Tilo Winkler; Robert Scott Harris; Vanessa Jane Kelly; Mamary Kone; Ira Katz; Andrew Martin; George Caillibotte; Dean R Hess; Jose G Venegas
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-29       Impact factor: 2.849

Review 7.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.